DeepMatter subsidiary signs data licensing agreement with the Life Science business of Merck DeepMa4 Nov 2021 12:05
DeepMatter subsidiary signs data licensing agreement with the Life Science business of Merck
DeepMatter Group plc, the AIM-quoted company focusing on digitising chemistry, is pleased to announce that one of its wholly owned subsidiaries has entered into a multi-year, limited-use data licensing agreement with the Life Science business of Merck to provide proprietary chemical structure and reaction data content to Merck's selected application.
Merck, a leading science and technology company, operates across Healthcare, Life Science and Performance Materials. The terms of the data license agreement have not been disclosed.
Mark Warne, CEO of DeepMatter commented: "We are delighted to have entered into this license with Merck, a company dedicated to making research and biotech simpler, faster and safer."